Dimensional Fund Advisors LP Sells 16,421 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Dimensional Fund Advisors LP cut its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 886,334 shares of the biotechnology company’s stock after selling 16,421 shares during the quarter. Dimensional Fund Advisors LP owned 1.99% of United Therapeutics worth $134,529,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. JJJ Advisors Inc. grew its holdings in shares of United Therapeutics by 775.0% during the 4th quarter. JJJ Advisors Inc. now owns 245 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 217 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in United Therapeutics during the fourth quarter valued at about $43,000. Signaturefd LLC grew its stake in shares of United Therapeutics by 54.0% during the fourth quarter. Signaturefd LLC now owns 308 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 108 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of United Therapeutics by 42.2% in the fourth quarter. Parallel Advisors LLC now owns 590 shares of the biotechnology company’s stock worth $90,000 after buying an additional 175 shares during the period. Finally, Veriti Management LLC bought a new stake in shares of United Therapeutics in the 4th quarter valued at about $135,000. Hedge funds and other institutional investors own 90.09% of the company’s stock.

In other news, Director Judy D. Olian sold 2,103 shares of the firm’s stock in a transaction that occurred on Wednesday, March 17th. The stock was sold at an average price of $170.00, for a total value of $357,510.00. Following the completion of the transaction, the director now owns 7,893 shares in the company, valued at approximately $1,341,810. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Judy D. Olian sold 4,207 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 1st. The shares were sold at an average price of $184.96, for a total value of $778,126.72. Following the sale, the director now owns 9,997 shares in the company, valued at $1,849,045.12. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.

A number of equities analysts have commented on UTHR shares. Oppenheimer lifted their price target on United Therapeutics from $200.00 to $275.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 16th. Cowen raised their target price on shares of United Therapeutics from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Wednesday, January 20th. HC Wainwright upgraded shares of United Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $125.00 to $195.00 in a report on Monday, February 1st. Credit Suisse Group increased their price target on shares of United Therapeutics from $169.00 to $196.00 and gave the company an “outperform” rating in a research report on Monday, March 1st. Finally, Wedbush boosted their price objective on shares of United Therapeutics from $255.00 to $260.00 and gave the company an “outperform” rating in a research report on Thursday, February 25th. They noted that the move was a valuation call. Eight analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $207.57.

Shares of United Therapeutics stock opened at $191.10 on Thursday. The business has a 50 day moving average of $170.31 and a 200 day moving average of $147.53. United Therapeutics Co. has a 52 week low of $94.09 and a 52 week high of $200.00. The company has a market cap of $8.51 billion, a PE ratio of 18.08 and a beta of 0.52. The company has a quick ratio of 6.88, a current ratio of 7.22 and a debt-to-equity ratio of 0.24.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Tuesday, February 23rd. The biotechnology company reported $2.19 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.96 by ($0.77). The company had revenue of $384.90 million for the quarter, compared to analysts’ expectations of $362.04 million. United Therapeutics had a net margin of 33.25% and a return on equity of 15.48%. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.96 earnings per share. On average, research analysts anticipate that United Therapeutics Co. will post 12.55 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Article: Market Capitalization – What it Means for Investors

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.